Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which PAH treatment strategy works better: adding a third drug or increasing the dose?

NCT ID NCT07713914

Recruiting now Disease control Sponsor: University of Sao Paulo General Hospital Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study compares two ways to intensify treatment for people with pulmonary arterial hypertension (PAH) who are not doing well enough on standard dual therapy. One group adds a third type of medication (a prostacyclin pathway agent), while the other group increases the dose of their existing sildenafil. The goal is to see which approach helps more patients improve their risk category within 3 to 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
prostacyclin pathway agent (inhaled iloprost or oral selexipag) or sildenafil dose optimization
What this could lead to
If successful, this study could show that adding a prostacyclin pathway agent is more effective than simply increasing the sildenafil dose for improving risk status in PAH patients.
What could go wrong
This is a relatively small, open-label trial, so results may be influenced by bias. The benefit of triple therapy over dose optimization may be modest or not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY ARTERIAL HYPERTENSION (PAH)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Instituto do Coração (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo

    RECRUITING

    São Paulo, São Paulo, 04551-060, Brazil

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.